Dublin, Nov. 23, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drugs: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global market for antibody drugs should grow from $126.7 billion in 2021 to $208.6 billion by 2026 with a compound annual growth rate (CAGR) of 10.5% for the period of 2021-2026.
The human antibody drugs market should grow from $58.4 billion in 2021 to $110.3 billion by 2026 with a compound annual growth rate (CAGR) of 13.6% for the period of 2021-2026.
The humanized antibody drugs market should grow from $50.1 billion in 2021 to $79.3 billion by 2026 with a compound annual growth rate (CAGR) of 9.6% for the period of 2021-2026.
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.
The publisher analyzes and makes projections of each market and its applications, along with an analysis of the regulatory environment, new products, and technological advances. Also included in the report are relevant patent analyses and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd., and Merck & Co.
The report covers the major markets of the U.S., Europe, and the emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and others.
Monoclonal antibodies are protein-based therapies/drugs that are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis, and cardiovascular diseases.
The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human, and humanized antibodies.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use.
The Report Includes
30 data tables and 29 additional tables
An overview of the global market for antibody drugs and related applications and technologies
Analyses of global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
Identification of new opportunities, challenges, and technological changes within the industry and highlights of the market potential for antibody drugs by type, application, and region
Detailed analysis of the current market trends, market forecast, and discussion of technological, and regulatory elements that are affecting the future marketplace
Details of antibody functions, its comparison with antigen, and description of monoclonal antibodies, their history, advantages and disadvantages, types, manufacturing technologies and applications
Coverage of new approvals, recalls, safety alerts and clinical trials of monoclonal antibodies and information on technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
Information about major technologies for the formulation of antibody drugs and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
Comprehensive company profiles of the leading players including F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., and Merck & Co.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Antibodies and Antigens
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
Chapter 4 Market Dynamics
Technical Issues and HAMA Problem
Human Anti-mouse Antibody (HAMA)
Factors Affecting mAb Drugs
Increasing Prevalence of Chronic Diseases
Advancements in Manufacturing Technologies
New Product Launches
Licensing and Collaboration Agreements
Regulatory Approval Pressures
Entry of Biosimilars
Impact of COVID-19 on Antibody Drugs Market
Chapter 5 Market Breakdown by Technology Type
Market by Type
Market by Region
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Human Monoclonal Antibodies
Murine Monoclonal Antibodies
Market by Manufacturing Process
Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process
Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
Market of Murine Monoclonal Antibodies by Manufacturing Process
Chapter 6 Market Breakdown by Application
Market by Diseases
Lymphoma, Leukemia and Multiple Myeloma
Chapter 7 Regulatory Aspects
New Approvals of Monoclonal Antibodies
Recalls and Safety Alerts
Chapter 8 Patent Review/ New Developments
Clinical Trial Phases
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
Chapter 9 Competitive Landscape
Mergers and Acquisitions
Market Shares of Humanized Monoclonal Antibodies
Market Shares of Human Monoclonal Antibodies
Market Shares of Chimeric Monoclonal Antibodies
Market Shares of Murine Monoclonal Antibodies
Chapter 10 Company Profiles
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ag
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Takeda Pharmaceutical Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/16g6t7
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900